Rebel Medicine Inc has successfully closed a $6 million Series A financing round while simultaneously receiving FDA clearance for its Investigational New Drug (IND) application for Alevatrix, the company's lead non-opioid pain therapeutic candidate. The dual milestone positions the Salt Lake City-based biotechnology company to advance its innovative approach to post-operative pain management into human clinical trials.
Series A Financing Details
The financing round was led by Crocker Ventures with participation from Central Texas Angel Network (CTAN), Prosperity Solutions Capital, Utah Innovation Fund, SK Hart, the Joan & Tim Fenton Fund, Cantina Angels, and a syndicate of experienced life-science angel investors. The proceeds will specifically fund a first-in-human, randomized, dose-escalation, active-controlled Phase 2 clinical trial in bunionectomy patients to assess the safety and efficacy of Alevatrix.
"This is a transformative moment for Rebel Medicine," said Brett Davis, PhD, Co-Founder and CEO of Rebel Medicine. "The successful Series A fundraise validates our vision and the potential of our technologies. Coupled with IND clearance for Alevatrix, it enables us to accelerate clinical development of Alevatrix and bring our opioid-sparing pain therapies to patients faster."
Alevatrix Technology Platform
Alevatrix represents a novel approach to post-operative pain management through its proprietary drug delivery system. The therapeutic is a long-acting formulation of bupivacaine, a well-characterized local anesthetic, encapsulated in Rebel Medicine's proprietary injectable matrix. The formulation is designed to release drug at the site of administration for up to 72 hours, with the primary goal of reducing or eliminating the need for opioids after surgery and their associated risks.
In preclinical studies, Alevatrix demonstrated prolonged, multi-day non-opioid analgesia with a favorable safety profile, supporting its advancement into human clinical trials.
Company Strategy and Pipeline
Rebel Medicine leverages its proprietary drug delivery technologies to enhance the functionality of validated active pharmaceutical ingredients. This approach is designed to create novel, high-value, extended-release therapeutics that address urgent unmet clinical needs while reducing development time, cost and risk compared to developing entirely new drug compounds.
Beyond Alevatrix, the company has additional pipeline programs in development that utilize Rebel's proprietary delivery systems to provide extended-release of injectable drugs from days to months, indicating a broader platform approach to drug delivery innovation.
